Search Results - Collaboration+Sought+%3e+Collaboration

616 Results

Sort By:

Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy

Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...

Published: 7/15/2025 | Inventor(s): Jay Berzofsky, Shweta Tiwary

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling

This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...

Published: 7/15/2025 | Inventor(s): Anagha Rama Varma, Parnika Kant, Kaitlyn Sadtler, Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Madison Daminato

Keywords(s):

Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Application > Therapeutics, ResearchProducts > Human Cell Lines, ResearchProducts > Research Equipment, TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Synergistic Interactions for Improved Cancer Treatment

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...

Published: 6/27/2025 | Inventor(s): Barbara Felber, George Pavlakis, Sevasti Karaliota, Dimitrios Stellas

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy...

Published: 6/11/2025 | Inventor(s): Young-Hwan Jung, Zhiwei Wen, Kenneth Jacobson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy

This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency,...

Published: 5/14/2025 | Inventor(s): Kenneth Jacobson, Dilip Tosh

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition

This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide...

Published: 6/11/2025 | Inventor(s): Ross Cheloha, Shubhra Saha

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Reproductive Health

PET Imaging Agents for Fungal Infections

Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections. Fungal infections remain a global health problem resulting in over 1.5 million annual deaths. Immunocompromised patients, especially those undergoing cancer treatments or...

Published: 6/9/2025 | Inventor(s): Dima Hammoud, Swati Shah, Peter Williamson, Rolf Swenson, Xiang Zhang, Falguni Bhattacharyya

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Collaboration Sought > Licensing

Broadly neutralizing influenza hemagglutinin stem-directed antibodies

In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance...

Published: 5/8/2025 | Inventor(s): Sarah Andrews, Grace Mantus, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Julie Raab

Keywords(s):

Category(s): Application, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions

The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...

Published: 5/8/2025 | Inventor(s): Patrick Duffy, Jonathan Renn

Keywords(s):

Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Francisella Lipids as Broad Anti-inflammatory Therapeutics

Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications...

Published: 5/13/2025 | Inventor(s): Catharine Bosio, Glenn Nardone, Robin Ireland

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Immunology

1 2 3 4 5 6 7 8 9 10 ...